Home
About
Leadership
Science
Investors
IR Kit
Tear Sheet
Press Releases
Stock Quotes
SEC Filings
Key Contacts
Subscribe to Email Alerts
News
Contact
Stay Ahead
|
|
Search for:
News
May 25, 2022
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
April 13, 2022
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
April 6, 2022
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
January 25, 2022
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 18, 2022
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
November 17, 2021
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
September 28, 2021
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
August 24, 2021
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets
August 12, 2021
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company’s Scientific Advisory Board
July 20, 2021
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
July 6, 2021
Temple research finds that tweaking CBD may help it curb pain and opioid use in mice
May 20, 2021
Philly Pharmacologists Are Developing a Promising Pain-Relieving CBD Analog Drug
November 6, 2020
Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol
September 17, 2020
Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors
June 30, 2020
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
April 14, 2020
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD
April 1, 2020
Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
February 18, 2020
Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent
February 11, 2020
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN
January 28, 2020
Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead
Home
About
Leadership
Science
Investors
IR Kit
Tear Sheet
Press Releases
Stock Quotes
SEC Filings
Key Contacts
Subscribe to Email Alerts
News
Contact